The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
Hanks, S. K., & Hunter, T. R. (1995) · PubMed · Cited by 2,518
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1
Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318
Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,154
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Harrison’s Principles of Internal Medicine
Malani, P. N. (2012) · JAMA · doi:10.1001/jama.308.17.1813-b · Cited by 2,039
Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects
Sherman, W., Day, T., Jacobson, M. P., Friesner, R. A., & Farid, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050540c · Cited by 2,031
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Self-citationThe JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Nolen, B., Taylor, S., & Ghosh, G. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.024 · Cited by 1,167
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862343 · Cited by 960
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Self-citationKornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA
Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., & Kuriyan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81443-9 · Cited by 720
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
Yamaoka, K., Saharinen, P., Pesu, M., Holt, V. E., Silvennoinen, O., & O'Shea, J. J. (2004) · Genome Biology · doi:10.1186/gb-2004-5-12-253 · Cited by 635
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Self-citationCD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling
Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G., Griffiths, E., Krawczyk, C., Richardson, C. D., Aitken, K., et al. (2001) · Nature · doi:10.1038/35053086 · Cited by 562
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Self-citationA helix scaffold for the assembly of active protein kinases
Kornev, A. P., Taylor, S. S., & Ten Eyck, L. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807988105 · Cited by 442
Shah, K., Liu, Y., Deirmengian, C., & Shokat, K. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3565 · Cited by 417
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 400
Kinase Drug Discovery – What’s Next in the Field?
Cohen, P., & Alessi, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb300610s · Cited by 377
Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain
Saharinen, P., Takaluoma, K., & Silvennoinen, O. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3387-3395.2000 · Cited by 365
Feng, J., Witthuhn, B. A., Matsuda, T., Kohlhuber, F., Kerr, I. M., & Ihle, J. N. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2497 · Cited by 356
Mesa, R. A., Silverstein, M. N., Jacobsen, S. J., Wollan, P. C., & Tefferi, A. (1999) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199905)61:1<10::aid-ajh3>3.0.co;2-i · Cited by 354
The molecular regulation of Janus kinase (JAK) activation
Babon, J. J., Lucet, I. S., Murphy, J. M., Nicola, N. A., & Varghese, L. N. (2014) · Biochemical Journal · doi:10.1042/bj20140712 · Cited by 326
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Kawamura, M., McVicar, D. W., Johnston, J. A., Blake, T. B., Chen, Y. Q., Lal, B. K., Lloyd, A. R., Kelvin, D. J., Staples, J. E., Ortaldo, J. R., et al. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6374 · Cited by 302
Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206478 · Cited by 281
Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C.-F., Neubert, T. A., Skoda, R. C., Hubbard, S. R., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2099 · Cited by 276
MEK1/2 dual-specificity protein kinases: Structure and regulation
Roskoski, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.145 · Cited by 276
Self-citationWilliams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., & Lucet, I. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.041 · Cited by 270
Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., Mann, D. W., & Mitton‐Fry, M. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12101 · Cited by 264
Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14403 · Cited by 263
Cerquozzi, S., & Tefferi, A. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.95 · Cited by 250
Tyner, J. W., Bumm, T. G., Deininger, J., Wood, L., Aichberger, K. J., Loriaux, M. M., Druker, B. J., Burns, C. J., Fantino, E., & Deininger, M. W. (2010) · Blood · doi:10.1182/blood-2009-05-223727 · Cited by 240
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Self-citationSantos, F. P. S., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J., & Verstovsek, S. (2010) · Blood · doi:10.1182/blood-2009-10-246363 · Cited by 233
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A., Laborde, R. R., Lasho, T. L., Finke, C., Begna, K., Al-Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A., Kowalski, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 233
Evolution of the eukaryotic protein kinases as dynamic molecular switches
Taylor, S. S., Keshwani, M. M., Steichen, J. M., & Kornev, A. P. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0054 · Cited by 233
Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R., & Eigenbrot, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401180111 · Cited by 229
Chrencik, J. E., Patny, A., Leung, I. K., Korniski, B., Emmons, T. L., Hall, T., Weinberg, R. A., Gormley, J. A., Williams, J. M., Day, J. E., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.020 · Cited by 227
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 218
Self-citationDeciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Meharena, H. S., Chang, P., Keshwani, M. M., Oruganty, K., Nene, A. K., Kannan, N., Taylor, S. S., & Kornev, A. P. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001680 · Cited by 208
The changing landscape of biosimilars in rheumatology
Dörner, T., Strand, V., Cornes, P., Gonçalves, J., Gulácsi, L., Kay, J., Kvien, T. K., Smolen, J., Tanaka, Y., & Burmester, G. R. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209166 · Cited by 194
Gauzzi, M. C., Velazquez, L., McKendry, R., Mogensen, K. E., Fellous, M., & Pellegrini, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20494 · Cited by 187
Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P. J., Rumi, E., Gattoni, E., Pieri, L., Guglielmelli, P., Elena, C., et al. (2014) · Cancer · doi:10.1002/cncr.28441 · Cited by 179
Furqan, M., Mukhi, N., Lee, B., & Liu, D. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-5 · Cited by 170
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src
Liu, Y., Shah, K., Yang, F., Witucki, L. A., & Shokat, K. M. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00099-6 · Cited by 156
Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Walsh, K. A., Follis, S. L., King, V. I., Tena, J., & Stegemann, M. R. (2013) · Veterinary Dermatology · doi:10.1111/vde.12088 · Cited by 155
Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., & Kaneko, Y. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208279 · Cited by 152
An update on the treatment of canine atopic dermatitis
Saridomichelakis, M. N., & Olivry, T. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.09.016 · Cited by 146
Autophosphorylation of JAK2 on Tyrosines 221 and 570 Regulates Its Activity
Argetsinger, L. S., Kouadio, J.-L. K., Steen, H., Stensballe, A., Jensen, O. N., & Carter‐Su, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4955-4967.2004 · Cited by 146
JAK2 activation by growth hormone and other cytokines
Waters, M. J., & Brooks, A. J. (2015) · Biochemical Journal · doi:10.1042/bj20141293 · Cited by 141
Namour, F., Diderichsen, P. M., Cox, E. H., Vayssière, B., der Aa, A. V., Tasset, C. T., & Klooster, G. A. E. V. '. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0240-z · Cited by 138
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Menet, C. J., Fletcher, S. R., Lommen, G. V., Geney, R., Blanc, J., Smits, K., Jouannigot, N., Deprez, P., van der Aar, E. M., Clément-Lacroix, P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501262q · Cited by 131
Zhou, Y., Hanson, E. P., Chen, Y., Magnuson, K. S., Chen, M., Swann, P. G., Wange, R. L., Changelian, P. S., & O’Shea, J. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13850 · Cited by 125
STATs: An Old Story, Yet Mesmerizing
Saeid, A., Saki, N., Ahmadvand, M., Asghari, F., Salari, F., & Rahim, F. (2016) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 124
Prevalence of polycythemia vera and essential thrombocythemia
Ma, X., Vanasse, G. J., Cartmel, B., et al. (2008) · American Journal of Hematology · doi:10.1002/ajh.21129 · Cited by 113
Introduction to the Immune System
McComb, S., Thiriot, A., Krishnan, L., & Stark, F. C. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-589-7_1 · Cited by 107
Little, P. R., King, V. L., Davis, K. R., Cosgrove, S. B., & Stegemann, M. R. (2014) · Veterinary Dermatology · doi:10.1111/vde.12186 · Cited by 105
The JAK kinases: Not just another kinase drug discovery target
Wilks, A. F. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.07.020 · Cited by 97
Two Clinical Phenotypes in Polycythemia Vera
Spivak, J. L., Considine, M., Williams, D. M., Talbot, C. C., Rogers, O. C., Moliterno, A. R., Jie, C., & Ochs, M. F. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403141 · Cited by 95
Farmer, L. J., Ledeboer, M. W., Hoock, T. C., Arnost, M. J., Bethiel, R. S., Bennani, Y. L., Black, J., Brummel, C. L., Chakilam, A. R., Dorsch, W. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00301 · Cited by 91
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F
Ma, L., Clayton, J. R., Walgren, R. A., Zhao, B., Evans, R. J., Smith, M. C., Heinz-Taheny, K. M., Kreklau, E. L., Bloem, L. J., Pitou, C., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.6 · Cited by 78
Phosphorylation of Jak2 on Ser 523 InhibitsJak2-Dependent Leptin ReceptorSignaling
Ishida-Takahashi, R., Rosario, F., Gong, Y., Kopp, K., Stancheva, Z. S., Chen, X., Feener, E. P., & Myers, M. G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01589-05 · Cited by 65
Mahajan, S., Hogan, J. K., Shlyakhter, D., Oh, L., Salituro, F. G., Farmer, L. J., & Hoock, T. C. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221176 · Cited by 65
Geyer, H. L., Scherber, R. M., Kosiorek, H., Dueck, A. C., Kiladjian, J., Xiao, Z., Slot, S., Zweegman, S., Sackmann, F., Fuentes, A. E. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9337 · Cited by 64
Springuel, L., Renauld, J., & Knoops, L. (2015) · Haematologica · doi:10.3324/haematol.2015.132142 · Cited by 64
Mazurkiewicz-Muñoz, A. M., Argetsinger, L. S., Kouadio, J.-L. K., Stensballe, A., Jensen, O. N., Cline, J. M., & Carter‐Su, C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01591-05 · Cited by 63
Schleicher, S. M. (2016) · Clinics in Podiatric Medicine and Surgery · doi:10.1016/j.cpm.2016.02.004 · Cited by 62
Genovese, M. C., Yang, F., Østergaard, M., & Kinnman, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208901 · Cited by 52
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Bryan, J. C., & Verstovšek, S. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3012-z · Cited by 45
Poulsen, A., William, A. D., Blanchard, S., Lee, A. H. Y., Nagaraj, H., Wang, H., Teo, E.-L., Tan, E., Goh, K. C., & Dymock, B. W. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-012-9572-z · Cited by 44
Argetsinger, L. S., Stuckey, J. A., Robertson, S., Koleva, R., Cline, J. M., Marto, J. A., Myers, M. G., & Carter‐Su, C. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0355 · Cited by 39
Waters, M. J., Brooks, A. J., & Chhabra, Y. (2014) · JAK-STAT · doi:10.4161/jkst.29569 · Cited by 36
Canine and Human Atopic Dermatitis: Two Faces of the Same Host-Microbe Interaction
Santoro, D., & Hoffmann, A. R. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.03.015 · Cited by 24
Atopic dermatitis in the domestic dog
Pucheu‐Haston, C. M. (2015) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2015.10.010 · Cited by 19
Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis
Sofia, M. A., & Rubin, D. T. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16643242 · Cited by 16
Cited by
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Liu, J., Han, X., Zhang, T., Tian, K., Li, Z., & Luo, F. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01512-7 · Cited by 660
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Self-citation
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 111
- Pages
- 784-803
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2481496926
- Cited by
- 373
- References
- 90
- FWCI
- 15.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.